Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | WDR5 | P61964 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | MERTK | Q12866 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356718 | 0.96 | GPR119 (0.44) | GPR119LRRK2KMT2AWDR5CYP3A4 | |
| SCHEMBL355772 | 0.96 | GPR119 (0.44) | GPR119LRRK2KMT2AWDR5CYP3A4 | |
| SCHEMBL355773 | 0.96 | GPR119 (0.44) | GPR119LRRK2KMT2AWDR5CYP3A4 | |
| SCHEMBL10172683 | 0.94 | GPR119 (0.45) | GPR119LRRK2KMT2ACYP3A4CYP2C9 | |
| SCHEMBL10172167 | 0.94 | GPR119 (0.44) | GPR119LRRK2KMT2ACYP3A4CYP2C9 | |
| SCHEMBL10171913 | 0.94 | GPR119 (0.44) | GPR119LRRK2KMT2ACYP3A4CYP2C9 | |
| SCHEMBL10172162 | 0.92 | GPR119 (0.43) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10172633 | 0.92 | GPR119 (0.43) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10171822 | 0.90 | GPR119 (0.42) | GPR119LRRK2KMT2AWDR5CYP3A4 | |
| SCHEMBL10172690 | 0.90 | GPR119 (0.42) | GPR119LRRK2KMT2AWDR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| WO-2010084944-A1 | NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND | 田辺三菱製薬株式会社 (JP) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | GPR119 1/4885LRRK2 2211/4885KMT2A 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.